Changes in tumor metabolic activity have been shown to be an early indicator of treatment
effectiveness for breast cancer, mainly in the neoadjuvant setting. The histopathologic …

Objectives The aim of this meta-analysis was to evaluate the accuracy of 18 F-FDG PET/CT
in predicting the pathological response to neoadjuvant chemotherapy (NAC) in breast …

Patients with locally advanced invasive breast cancers are often treated with neoadjuvant
chemotherapy prior to definitive surgical intervention. The primary aims of this approach are …

Purpose To investigate parameters based on fluorine 18 fluorodeoxyglucose (FDG) positron
emission tomographic (PET) imaging that are best correlated with pathologic complete …

Early assessment of response to neoadjuvant chemotherapy (NAC) might be helpful in
avoiding the toxicity of ineffective chemotherapy and allowing refinement of treatment. We …

Purpose: To investigate the value of the metabolic tumor response assessed with 18F-
fluorodeoxyglucose positron emission tomography (FDG-PET), compared with …

In this manuscript, we review the current progress of utilizing ultrasound-guided diffuse
optical tomography (US-guided DOT) for predicting and monitoring neoadjuvant …

Metabolic reprogramming is not only an emerging hallmark of cancer, but also an essential
regulator of cancer cell adaptation to the microenvironment. Metabolic imaging targeting …

The goals of precision oncology are to provide targeted drug therapy based on each
individual's specific tumor biology, and to enable the prediction and early assessment of …

Although neoadjuvant chemotherapy (NAC) is a crucial component of treatment for locally
advanced breast cancer (LABC), only about 70% of patients respond to it. Effective …